Perilous Reversal Stock: Array BioPharma (ARRY)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Array BioPharma ( ARRY) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Array BioPharma as such a stock due to the following factors:

  • ARRY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $14.2 million.
  • ARRY has traded 79,426 shares today.
  • ARRY is down 3% today.
  • ARRY was up 13.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ARRY with the Ticky from Trade-Ideas. See the FREE profile for ARRY NOW at Trade-Ideas

More details on ARRY:

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Currently there are 6 analysts that rate Array BioPharma a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Array BioPharma has been 2.2 million shares per day over the past 30 days. Array BioPharma has a market cap of $873.1 million and is part of the health care sector and drugs industry. The stock has a beta of 1.78 and a short float of 25% with 12.64 days to cover. Shares are up 33.6% year-to-date as of the close of trading on Friday.

If you liked this article you might like

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Mirati Skyrockets On Positive Data - Biotech Movers

Array BioPharma Seems to Be in a New Uptrend